The value of long noncoding RNA PANDAR as a biomarker of prognosis in carcinomas: a meta-analysis

Abstract

Promoter of CDKN1A antisense DNA damage activated RNA (PANDAR) has been demonstrated to be aberrantly expressed in various types of cancer and might be serve as a potential biomarker for human cancers. The present study conducted a meta-analysis to investigate whether the expression of lncRNA PANDAR was associated with prognosis and clinicopathological features in relevant cancers. 10 eligible studies with a total of 1211 patients were collected by searching the electronic bibliographic databases, the results show that high expression level of PANDAR could significantly predict shorter OS in cancer patients (HR = 2.08, 95% CI: 1.55-2.80, P < 0.001) except in patients with non-small cell lung cancer (NSCLC). There was also a significant association between high level of PANDAR and advanced TNM stage (OR = 2.80, 95% CI = 1.57-4.99, P < 0.001), positive lymph node metastasis (OR = 2.92, 95% CI = 1.92-4.45, P < 0.001), larger tumor size (OR = 1.41, 95% CI = 1.04-1.89, P = 0.03) and poor tumor differentiation (OR = 1.53, 95% CI = 1.09-2.15, P = 0.01). In conclusion, the meta-analysis results indicate that increased expression level of PANDAR was associated with unfavorable prognosis and might serve as a predictive factor for advanced clinicopathological features in various cancers.